Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?

Affiliations

¹ Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. ilaria.delgiudice@uniroma1.it.
² Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. rfoa@bce.uniroma1.it.

Review

Ilaria Del Giudice et al. Leukemia. 2023 Dec.

. 2023 Dec;37(12):2339-2342.

doi: 10.1038/s41375-023-02066-w. Epub 2023 Oct 14.

¹ Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. ilaria.delgiudice@uniroma1.it.
² Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. rfoa@bce.uniroma1.it.

No abstract available

References

1. Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, et al. Minimal residual disease in chronic lymphocytic leukemia: a new goal? Front Oncol. 2019;9:689. - DOI - PubMed - PMC
1. Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980–8. - DOI - PubMed
1. Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9. - DOI - PubMed - PMC
1. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921–4. - DOI - PubMed - PMC
1. Moia R, Dondolin R, De Propris MS, Talotta D, Mouhssine S, Perutelli F, et al. Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. Hematol Oncol. 2023;41:567–0. - DOI - PubMed